Research Press Releases Data analysis
Sean Davis, MD, PhD, associate director of informatics and data science at the University of Colorado Cancer Center, is part of a team that recently received a $5.2 million grant renewal from the National Institutes of Health (NIH) to continue funding cancer genomics research.
Press Releases Community Research Pharmacy Community Health
Jeanette Waxmonsky, PhD, associate clinical professor in the Colorado School of Public Health and associate clinical professor of family medicine in the University of Colorado School of Medicine, has been named assistant director for community-engaged research for the Office of Community Outreach and Engagement at the CU Cancer Center.
Research Press Releases Gynecologic Cancer Endometrial Cancer
The results of a multisite clinical trial overseen by University of Colorado Cancer Center member Bradley Corr, MD, could offer new hope to patients with metastatic and recurrent uterine cancer, also known as endometrial cancer.
Research Press Releases Colorectal Cancer
On a mission to put an end to colorectal cancer, the Colorectal Cancer Alliance (CCA) recently launched Project Cure CRC, an initiative aimed at funding tens of millions of dollars in expedited, novel colorectal cancer research over the next two years.
Press Releases Equity Diversity and Inclusion Leadership
The University of Colorado Cancer Center is doubling down on its diversity, equity, inclusion, and access (DEIA) efforts in 2023, adding an associate director and deputy associate director of DEIA to its leadership team.
A new study published in Gastroenterologyaims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett’s esophagus (BE).
Research Press Releases Cancer
A new study published in the Journal of the National Cancer Institutebrings researchers and oncologists one step closer to better understanding the complexities of PD-1 inhibitors, a common type of immunotherapy, and their intracellular signaling on cancer behavior.
Research Press Releases Pancreatic Cancer Clinical Trials
A unique treatment combining radiation and immunotherapy can eradicate pancreatic tumors while stopping the cancer from spreading, according to a new study by researchers at the University of Colorado Cancer Center.
The Protocol Review and Monitoring System (PRMS) in the University of Colorado Cancer Center’s Clinical Trials Office is under new leadership.
Researchers from the University of Colorado Anschutz Medical Campus have identified a new feature indicative of the chance of recurrence of Gastrointestinal Stromal Tumors (GISTs).
Research Press Releases Pancreatic Cancer
Today, the University of Colorado Cancer Center released new research that showcases chemotherapy treatment before and after surgery for pancreatic cancer as the most effective combination for patients.
Press Releases Head and Neck Cancer Cancer
A new study from researchers at the University of Colorado Anschutz Medical Campus has identified a less invasive way to treat a subset of head and neck cancers that could potentially change the standard of care for patients.
Press Releases Community ColoradoSPH at CU Anschutz Leadership
Jan Lowery, PhD, MPH, who started her career as a researcher at the University of Colorado Cancer Center, returned September 1 as assistant director for dissemination and implementation for the Office of Community Outreach and Engagement at the CU Cancer Center. In her new role, Lowery will lead efforts to develop, conduct, and disseminate implementation-focused projects in cancer prevention, early detection, and survivorship.
Research Press Releases Lung Cancer
A new study from the University of Colorado Cancer Center explores which lung cancer patients are the best candidates for novel therapies that directly target a gene identified as driving certain cancers.
Press Releases Pediatric Cancer Blood Cancer Brain and Spinal Cancer Ovarian Cancer
Three researchers from the University of Colorado Cancer Center have received grants from the V Foundation, a cancer research nonprofit founded in 1993 by college basketball coach Jimmy Valvano, who died of cancer.
A consortium of 17 cancer centers around the country have come together to better understand the consequences of the COVID-19 pandemic as it relates to delayed cancer detection, care and prevention.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Greg Glasgow
